Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 8/20 | 0.71 |
| ▸ | JAK2 | O60674 | 2/20 | 0.71 |
| ▸ | BTK | Q06187 | 8/20 | 0.69 |
| ▸ | FYN | P06241 | 3/20 | 0.69 |
| ▸ | FLT1 | P17948 | 2/20 | 0.69 |
| ▸ | KDR | P35968 | 2/20 | 0.69 |
| ▸ | SRC | P12931 | 2/20 | 0.69 |
| ▸ | STK16 | O75716 | 1/20 | 0.69 |
| ▸ | AURKA | O14965 | 2/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | PAK4 | O96013 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679560 | 1.00 | JAK3 (0.71) | JAK3JAK2BTKFYNFLT1 | |
| SCHEMBL14078241 | 1.00 | JAK3 (0.71) | JAK3JAK2BTKFYNFLT1 | |
| SCHEMBL1679647 | 0.91 | JAK3 (0.76) | JAK3JAK2BTKFYNFLT1 | |
| SCHEMBL1679267 | 0.87 | JAK3 (0.76) | JAK3JAK2BTKFYNFLT1 | |
| SCHEMBL1678960 | 0.86 | JAK3 (0.75) | JAK3JAK2BTKFYNFLT1 | |
| SCHEMBL1679413 | 0.86 | JAK3 (0.80) | JAK3JAK2BTKFYNFLT1 | |
| SCHEMBL14095914 | 0.84 | JAK3 (0.78) | JAK3JAK2BTKFYNFLT1 | |
| SCHEMBL4589805 | 0.83 | JAK3 (1.00) | JAK3JAK2BTKFYNFLT1 | |
| SCHEMBL12807466 | 0.83 | BTK (0.84) | JAK3JAK2BTKFYNFLT1 | |
| SCHEMBL12807501 | 0.82 | JAK3 (0.76) | JAK3JAK2BTKFYNFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329737-B2 | Benzimidazoles as selective kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2012-12-11 | — | — | US | disclosed |
| US-8329737-B2 | Benzimidazoles as selective kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2012-12-11 | — | — | US | disclosed |
| US-20110082142-A1 | SELECTIVE KINASE INHIBITORS | CYTOPIA RESEARCH PTY LTD (AU) | 2011-04-07 | — | — | US | disclosed |
| US-20110082142-A1 | SELECTIVE KINASE INHIBITORS | CYTOPIA RESEARCH PTY LTD (AU) | 2011-04-07 | — | — | US | disclosed |
| US-20080207613-A1 | Selective Kinase Inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2008-08-28 | — | — | US | disclosed |
| US-20080207613-A1 | Selective Kinase Inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2008-08-28 | — | — | US | disclosed |
| US-20080207613-A1 | Selective Kinase Inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082142-A1 | SELECTIVE KINASE INHIBITORS | LCK, CHUK, CSK | JAK3 47/4885JAK2 51/4885BTK 7/4885 |
| US-20080207613-A1 | Selective Kinase Inhibitors | LCK, CHUK, CSK | JAK3 47/4885JAK2 51/4885BTK 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.